KRT88P and cancer: Failure to produce anti-HBc after new HBV infections has mostly been described in immunocompromised patients, that is, in human immunodeficiency virus infection, in the context of transplantation,19,21 and after immunosuppressive cancer therapy.22 The effect of immunosuppression seemed to act stronger on HBV than on other pathogens in the recipient, because he was able to develop antibodies to transplantation-associated primary cytomegalovirus infection (unpublished data).